Abstracts tagged "B-Cell Targets"

Abstract Number: L17 • ACR Convergence 2024
Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Yiyi Yu¹, Ruina Kong¹, Xia Xu¹, Suxuan Liu¹, Qian Chen¹, Xiaofang Li², Ming Sun², Jianmin Yang¹, Dongbao Zhao¹ and Jie Gao¹, ¹Changhai Hospital, Shanghai, China, ²Rui Therapeutics, Nanjing, China
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
Abstract Number: 0006 • ACR Convergence 2024
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Mark Noviski¹, Jun Ma¹, Nivetha Brathaban¹, Aishwarya Kumar¹, Dhwani Haria¹, Jenny McKinnell¹, Robert Cass¹, Frederick Cohen¹, Davorka Messmer², Gwenn Hansen¹ and Ryan Rountree¹, ¹Nurix Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Diego, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) mediates signaling downstream of the B cell receptor (BCR), toll-like receptors (TLRs), and Fc receptors (FcRs). This makes BTK an…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 1551 • ACR Convergence 2024
Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Luca Iaccarino¹, Marisol Bracalenti², Alberto Cauli³, Lorenzo Cavagna⁴, Rossella De Angelis⁵, Roberto Depascale², Giacomo Emmi⁶, Roberto Gerli⁷, Marcello Govoni⁸, Alberto Lo Gullo⁹, Simone Negrini¹⁰, Luca Quartuccio¹¹, Maurizio Rossini¹², Carlo Salvarani¹³, Paola Tomietto¹⁴, Angelo Vacca¹⁵, Margherita Zen¹⁶ and doria Andrea², ¹University of Padua, PADOVA, Italy, ²University of Padova, Padova, Italy, ³University of Cagliari, Cagliari, Italy, ⁴University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶University of Trieste, Trieste, Italy, ⁷University of Perugia, Perugia, Italy, ⁸Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁹Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁰University of Genova, Genova, Italy, ¹¹Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹²Rheumatology Unit, University of Verona, Verona, Italy, ¹³Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁴Azienda Sanitaria Universitaria Giuliano Isontina, trieste, Italy, ¹⁵University of Bari, Bari, Italy, ¹⁶University of Padova, Padova, Padua, Italy
Background/Purpose: To evaluate the efficacy of belimumab on different skin and joint manifestations of the disease in a multicenter, nationwide, cohort (BeRLISS-NeJS) of patients with…
Abstract Number: 2436 • ACR Convergence 2024
Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
Florian Kollert¹, Sarah Robertson², Veit Erpenbeck², Franziska Regenass-Lechner³, Remy Hallet³, Jason Neale², Cary M. Looney², Nicolas Frances², Celine Marban-Doran², Sophia Fredrika Soehrman Brossard², Laurie Millar⁴, Beki Finch⁵, Johannes Sam⁶, Benjamin A. Fisher⁷, Maria Leandro⁸, Thomas Dörner⁹, Christian Klein¹⁰ and Franz Schuler², ¹University Hospital Basel, Basel, Switzerland, ²F. Hoffmann-La Roche Ltd., Basel, Switzerland, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴F. Hoffmann-La Roche Ltd., Welwyn Garden City, England, United Kingdom, ⁵F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom, ⁶F. Hoffmann-La Roche Ltd, Schlieren, Zurich, Switzerland, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University College London, London, United Kingdom, ⁹Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ¹⁰F. Hoffman-La Roche Ltd., Schlieren, Zurich, Switzerland
Background/Purpose: CD20-directed B-cell depletion therapy shows efficacy in hematological malignancies and in multiple autoimmune indications. More recently, promising data for the use of CD19-targeted B-cell…
Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 1646 • ACR Convergence 2024
A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE
Iolanda Miceli¹, Rochelle Sherlock², Pamela Hall², IanIan Cheang², Akshay D'Cruz³, Taylah Bennett², Terry Lim Kam Sian², Rangi Kandane-Rathnayake⁴, Eric Morand⁵ and Sarah Jones², ¹Monash University, Glen Iris, Victoria, Australia, ²Monash University, Melbourne, Australia, ³Monash University, Me, Australia, ⁴Monash University, Clayton, Victoria, Australia, ⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: SLE is primarily mediated by B cell dysregulation on a background of type I interferon (IFN) activation. This multi-faceted nature of immune defects in…
Abstract Number: 2437 • ACR Convergence 2024
Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE
Changming Lu¹, Jose Rubio², Hui-Chen Hsu¹ and John D. Mountz³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³University Alabama Birmingham, Birmingham, AL
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an increase in T-bet+ IgD−CD27− double negative 2 (DN2) B cells, attributed to heightened TLR7 signaling. Identifying…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 0776 • ACR Convergence 2024
Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation
Elliot Akama-Garren¹, Yingying Zhang², Balthasar Heesters³, Padraic Fallon⁴ and Michael Carroll², ¹Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Utrecht University, Utrecht, Netherlands, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Germinal center (GC) responses generate humoral immunity through coordinated interactions between B cells and T follicular helper (TFH) and T follicular regulatory (TFR) cells.…
Abstract Number: 1651 • ACR Convergence 2024
Unlocking the Secrets of Breg Dysfunction in Lupus: Glycosylation Patterns as Therapeutic Targets
Pauline Kerleroux-Trébaol¹, Marie Morel¹, Sandrine Jousse-Joulin², Divi Cornec³, Pierre Pochard¹ and Anne Bordron¹, ¹Université de Bretagne Occidentale, brest, France, ²cavale blanche hospital, brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France
Background/Purpose: The immune system is a complex network of cells preventing the invasion of the organism from external particles. The break in the homeostasis will…
Abstract Number: 2548 • ACR Convergence 2024
NADPH Oxidase in B Cells and Macrophages Protects Against Murine Lupus by Regulation of TLR7
Rachael Gordon¹, Haylee Cosgrove², Anthony Marinov³, Sebastien Gingras¹, Jeremy Tilstra², Allison Campbell⁴, Sheldon Bastacky¹, Andras Perl⁵, Kevin Nickerson¹ and Mark Shlomchik², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Homestead, PA, ⁴Yale, New Haven, ⁵SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by loss of tolerance to nuclear antigens, immune activation, and organ damage. Loss of…
Abstract Number: 0010 • ACR Convergence 2024
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Holly Wobma¹, Francesca Alvarez-Calderon², Jiayi Dong², Alexandre Albanese², Kayleigh Omdahl², Rene Bermea³, Gillian Selig⁴, Marlana Winschel², Elisa Rojas Palato², Katherine Michaelis¹, Xianliang Rui², Bruce Blazar⁵, Susan Prockop², Victor Tkachev³, Ulrike Gerdemann² and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Boston, MA, ⁵Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN
Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
Abstract Number: 0777 • ACR Convergence 2024
Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Theodoros Ioannis Papadimitriou¹, Jing Jing Wang², Xuehui He³, Sidney van der Zade⁴, Massis Krekorian⁵, Prashant Singh⁶, Erik Dik⁵, Ger Pruijn⁵, Tom Gordon², Hans Koenen⁷, Martijn Huijnen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Flinders University, Adeleide, Australia, ³Radboudumc, Nijmegen, Netherlands, ⁴Radboudumc, Amsterdam, Netherlands, ⁵Radboudumc, Nijmegen, Gelderland, Netherlands, ⁶Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.